No Photo Available

Last Update

2016-06-01T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong M. First?

Dr. M. Roy First

Vice President

Astellas Pharma Inc.

Direct Phone: (847) ***-****       

Email: m***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Astellas Pharma Inc.

2-5-1 Nihonbashi-Honcho

Tokyo, Tokyo 103-8411

Japan

Company Description

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neur ... more

Find other employees at this company (7,717)

Background Information

Employment History

Chief Marketing Officer

Transplant Genomics Inc

Online

Cleveland Clinic

Senior Director, Medical Affairs

Fujisawa Healthcare , Inc.

Director, Section of Transplantation

University of Cincinnati Medical Center

President

American Society of Transplant Physicians

Professor of Medicine, Director, Section of Transplantation

University of Cincinnati

Chairman

SAB

Education

M.D.

advanced degrees

medicine

South Africa

Web References (73 Total References)


Dr. Roy First Joins Transplant ...

www.biospace.com [cached]

Dr. Roy First Joins Transplant Genomics As Chief Medical Officer Tweet

4/30/2015 12:30:47 PM
BROOKLINE, Mass.--(BUSINESS WIRE)--Transplant Genomics Inc. (TGI) has announced the appointment of Dr. Roy First as its Chief Medical Officer as the company moves toward the launch of its first product, the TruGraf Blood Test. Most recently, Dr. First was the Vice President and Therapeutic Area Leader, Transplantation, at Astellas Pharma Global Development, Inc. He is a past President of the American Society of Transplantation (AST) and recipient of the AST Lifetime Achievement Award. His distinguished clinical and academic career includes professional appointments at major academic institutions and important roles in many organizations, such as the United Network for Organ Sharing, the U.S. Food and Drug Administration and the National Institutes of Health.


Dr. Roy First Joins ...

www.freshnews.com [cached]

Dr. Roy First Joins Transplant Genomics as Chief Medical Officer print this article - email to a friend - join our eNewsletter Submitted by admin on 4/30/2015 @ 4:00 AM Companies mentioned in this article: Transplant Genomics Inc.

BROOKLINE, Mass. -- (BUSINESS WIRE) -- Transplant Genomics Inc. (TGI) has announced the appointment of Dr. Roy First as its Chief Medical Officer as the company moves toward the launch of its first product, the TruGraf Blood Test. Most recently, Dr. First was the Vice President and Therapeutic Area Leader, Transplantation, at Astellas Pharma Global Development, Inc. He is a past President of the American Society of Transplantation (AST) and recipient of the AST Lifetime Achievement Award. His distinguished clinical and academic career includes professional appointments at major academic institutions and important roles in many organizations, such as the United Network for Organ Sharing, the U.S. Food and Drug Administration and the National Institutes of Health.
"I am very excited to be joining this innovative company on the cutting edge of applying genomic biomarkers to post-transplant management," commented Dr. First. "The ultimate goal is to be able to detect and respond to early signs of graft injury so as to improve management of the patient as well as graft outcomes. I am convinced that TruGraf has such capabilities and has the potential to extend graft and patient lives, and reduce healthcare costs."
"Roy is a widely respected leader in transplantation with a deep understanding of the field, and we are thrilled to have him join our team," explained Stan Rose, PhD, President & CEO of Transplant Genomics.


Dr. Roy First Joins Transplant ...

www.devicespace.com [cached]

Dr. Roy First Joins Transplant Genomics As Chief Medical Officer 4/30/2015 12:30:47 PM

BROOKLINE, Mass.--(BUSINESS WIRE)--Transplant Genomics Inc. (TGI) has announced the appointment of Dr. Roy First as its Chief Medical Officer as the company moves toward the launch of its first product, the TruGraf Blood Test. Most recently, Dr. First was the Vice President and Therapeutic Area Leader, Transplantation, at Astellas Pharma Global Development, Inc. He is a past President of the American Society of Transplantation (AST) and recipient of the AST Lifetime Achievement Award. His distinguished clinical and academic career includes professional appointments at major academic institutions and important roles in many organizations, such as the United Network for Organ Sharing, the U.S. Food and Drug Administration and the National Institutes of Health.


Roy First, vice president ...

www.communityresearch.com [cached]

Roy First, vice president and therapeutic area head of transplantation for Astellas Pharma Global Development in Northbrook, Ill., says Schroeder and CTI have developed a solid reputation in their specialty niches, especially transplant medicine.


NATCO - The Organization for Transplant Professionals

www.natco1.org [cached]

An Interview with M. Roy First, MD NATCO Research Awards Legislative Update

...
An Interview with M. Roy First
...
The 2013 American Society of Transplantation (AST) Lifetime Achievement Award was presented to M. Roy First, M.D. at the American Transplant Congress (ATC) meeting in Seattle, Wash. NATCO received a call offering the opportunity to interview Dr. First in the Press Room at the Convention Center. The call was appropriately forwarded to me to conduct the interview as part of our "Courage and Character, Leaders and Legends" series. Prior to most interviews, there is time to read publications written by the person to be interviewed. With short notice, only several articles were scanned but the opportunity to interview Dr. First was not going to be missed. I hurried to the Convention Center and arrived in time to see an impressive looking white haired man in a suit and tie being taken to the press room. I introduced myself to Dr. First and his staff, and we began our interview.
Dr. First's delightful South African accent made the interview even more interesting and pleasant. Having been born and raised in South Africa, Dr. First received his medical education in Johannesburg. He explained this educational program spanned six years at the University of Witwatersrand.
...
Dr. First was invited to join him in 1974 for a clinical fellowship in nephrology. Soon after completing his fellowship he was appointed assistant professor of medicine in the Division of Nephrology at the University of Cincinnati. Over the next 30 years in Cincinnati, his career flourished as he was promoted to full professor and director of transplantation. Steroid withdrawal became a great interest of Dr. First. He was involved with several studies that provided patients with steroid free therapies once withdrawn (1-4). These trials have led to less diabetes. Although there have been more rejection episodes in many of the steroid withdrawal recipients, long term graft outcomes have been similar in comparison with those patients who continued on steroids. We discussed how successful these programs have been in kidney and liver transplantation but not with thoracic transplantation. Our conversation quickly turned to immunosuppression and ways to manage the immune system. We discussed various tolerance studies conducted by Drs. Newell, Kirk and Starzl (5, 6) and how the road to tolerance has been paved with many disappointments but continued determination with numerous active protocols in the United States, Europe and Australia.
In addition to his role in nephrology at the University of Cincinnati, Dr. First also became involved in what is now known as the Israel Penn International Transplant Tumor Registry (7). He recalled that Dr. Penn presented a paper on four cases of Post Transplant Lymphoproliferative Disease (PTLD) at the first meeting of the International Transplant Society held in Paris in 1966. After his presentation, several physicians described similar experiences with this disease he called PTLD.
...
During his 30 years at the University of Cincinnati, Dr. First also held many professional leadership roles. In 1982 he met with a group of nephrologists and immunologists at meeting of the American Society of Transplant Surgeons in Chicago in 1982. They had a small conference room and began developing the structure of the American Society of Transplant Physicians (ASTP). A few years later he was elected President of ASTP, a position he held from 1990-1991. This association was later renamed as the American Society of Transplantation (AST). He served on numerous AST committees over the years and was one of the founders of the American Journal of Transplantation. In the 1990s he also served on many UNOS committees and has been a reviewer for the National Institute of Health Data and Safety Monitoring Board (DSMB) for clinical trials in transplantation. He has more than 400 publications in peer-reviewed journals as well as chapters in textbooks.
In 2002, Dr. First joined the pharmaceutical industry where he now serves as the Vice President and Therapeutic Area Head of Transplantation at Astellas. He continues to participate in publications involving trials of new immunosuppressive agents.
Conclusion
Dr. First has truly been an influential leader in the field of transplantation. His passion for understanding the immune system and finding medications to better manage and prevent rejection, led him to Astellas where he could influence studies to improve the outcomes of transplantation. With his work in the Tumor Registry he also has a clear understanding that we need to find medications that can manage the immune system in ways that will not increase the risk of malignancies. In receiving the prestigious Lifetime Achievement Award by AST this year, Dr. First has been recognized by his peers as having demonstrated characteristics of leadership with the courage to move our science for immunosuppression forward.

Similar Profiles

Other People with this Name

Other people with the name First

Brian First
The Eastside Montessori School

Palak First
American Hospital Association

I. First
I Know First Ltd

Brian First
Arch Insurance Group Inc

Elissa First
Huron Consulting Group Inc.

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory